{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ANTICIPATE","nct_id":"NCT04813107","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=anticipate-nct04813107. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ANTICIPATE","arms":[{"description":null,"label":"APL-1202 in combination with tislelizumab","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Tislelizumab alone","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-03-01","type":"ESTIMATED"},"conditions":["Muscle Invasive Bladder Cancer"],"enrollment":{"count":79,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"APL-1202 in combination with tislelizumab","otherNames":[],"type":"DRUG"},{"name":"Tislelizumab alone","otherNames":[],"type":"DRUG"}],"last_update":"2022-02-22","lead_sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","official_title":"A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2023-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Adverse events (AE) and serious adverse events (SAE).","timeFrame":"9 weeks"},{"measure":"The RP2D of APL-1202 in combination with tislelizumab.","timeFrame":"9 weeks"},{"measure":"The rate of pathologic complete response (pCR) in Phase 2.","timeFrame":"26 months"}],"references":[],"start_date":{"date":"2021-12-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT04813107"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/anticipate-nct04813107"}